AUS
NZ
UK
CA
USA
IND
Highlights:
AnaptysBio's Q3 2024 revenue of $30.0 million significantly exceeded the analyst estimate of $6.87 million, driven by collaboration revenue and a commercial milestone.
The company reported a net loss of $32.9 million for Q3 2024, an improvement from the previous year.
Strong cash position of $458.0 million as of September 30, 2024, providing financial stability to support future clinical and pipeline developments.
AnaptysBio Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company focused on developing antibody therapies for inflammatory and immuno-oncology indications, announced its financial results for the third quarter of 2024. The company’s performance highlighted both positive revenue growth and ongoing investments in its research pipeline.
For Q3 2024, AnaptysBio reported a total revenue of $30.0 million, a significant increase from $3.3 million in the same quarter of 2023. This growth was primarily driven by $15.0 million in commercial milestone payments linked to the sales of Jemperli and increased royalty revenues. The notable rise in collaboration revenue demonstrates the success of AnaptysBio's strategic partnerships and collaborations, which play a key role in supporting the company's operations and clinical trials.
The company posted a net loss of $32.9 million, an improvement from the $37.3 million loss in Q3 2023. This reduction in losses reflects more efficient financial management and ongoing progress in advancing the company's clinical-stage pipeline. The net loss per share for the quarter was $1.14, an improvement over the $1.41 loss per share reported in the same period last year, indicating better control over expenses.
As of September 30, 2024, AnaptysBio had a robust cash position with $458.0 million in cash, cash equivalents, and investments. This strong financial standing ensures the company has sufficient resources to fund its ongoing clinical trials and development programs through at least 2026. This includes pivotal Phase 2b trials for ANB032 in atopic dermatitis and rosnilimab in rheumatoid arthritis, which are expected to yield key data in late 2024 and early 2025.
AnaptysBio’s ability to secure substantial collaboration revenue while continuing to advance its clinical pipeline positions the company for sustained growth as it approaches several critical clinical milestones.
